Dyne Therapeutics, Inc.
DYN
$10.05
$0.202.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.84% | 11.84% | 98.98% | 89.83% | 66.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.66% | 49.37% | 42.01% | 46.52% | 39.28% |
| Operating Income | -62.66% | -49.37% | -42.01% | -46.52% | -39.28% |
| Income Before Tax | -60.28% | -42.63% | -34.54% | -41.51% | -36.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.28% | -42.63% | -34.54% | -41.51% | -36.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.28% | -42.63% | -34.54% | -41.51% | -36.08% |
| EBIT | -62.66% | -49.37% | -42.01% | -46.52% | -39.28% |
| EBITDA | -62.93% | -49.62% | -42.30% | -46.91% | -39.63% |
| EPS Basic | -7.80% | 9.36% | 14.86% | 0.77% | -5.32% |
| Normalized Basic EPS | -7.79% | 9.36% | 14.86% | 0.77% | -5.33% |
| EPS Diluted | -7.80% | 9.36% | 14.86% | 0.77% | -5.32% |
| Normalized Diluted EPS | -7.79% | 9.36% | 14.86% | 0.77% | -5.33% |
| Average Basic Shares Outstanding | 44.11% | 53.88% | 57.72% | 45.96% | 34.10% |
| Average Diluted Shares Outstanding | 44.11% | 53.88% | 57.72% | 45.96% | 34.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |